Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Fibrosis Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Entactin/NID1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Entactin/NID1 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View NID1 Products |
| Gene Delivery | Entactin/NID1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Conformation-preserving cell-based assays. |
View NID1 Products |
| Benchmark Ab | Anti-Entactin/NID1 Recombinant Antibody Recombinant positive control for assay validation. Sequence verified. |
View NID1 Products |
| Validator | Entactin/NID1 siRNA Set For knockdown verification and specificity controls. |
View NID1 Products |
| Related Target A | Laminin Subunit Alpha 1 (LAMA1) Primary basement membrane binding partner of NID1; essential for ECM bridge assay validation. |
View LAMA1 Products |
| Related Target B | Collagen Type IV Alpha 1 (COL4A1) Key structural partner of NID1; critical for evaluating basement membrane integrity. |
View COL4A1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity |
| Subfamily counter screening (NID2 vs NID1) | Homolog panel proteins strictly verified by mass spectrometry and theoretical MW |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live Entactin/NID1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Entactin/NID1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and multi-specific targeting of the tumor microenvironment. As first-generation basement-membrane targeting therapies reach the clinic, the next wave of R&D is targeting the disruption of NID1-mediated extracellular matrix (ECM) networks in metastatic solid tumors and fibrotic tissues.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Academic Institutes, Biotech Startups | Ovarian Cancer, Breast Cancer Metastasis | Epitope mapping & ligand blocking assays (Need sequence-verified ECD-Fc) |
| Bispecific / Multi-specific | Oncology-focused Biopharma | Solid Tumors (TME Targeting) | Heterodimer validation & cross-reactivity screening (Need high-purity orthologs) |
| siRNA / Gene Therapy | RNAi Therapeutics Developers | Pulmonary Fibrosis, Organ Fibrosis | In vitro knockdown verification (Need validated siRNA control sets) |